Top

Published in:

01-02-2016 | Original Article

Altered expression of LINC-ROR in cancer cell lines and tissues

Authors: Majdaddin Rezaei, Modjtaba Emadi-Baygi, Michèle J. Hoffmann, Wolfgang A. Schulz, Parvaneh Nikpour

Published in: Tumor Biology | Issue 2/2016

Abstract

According to GLOBOCAN 2012, the worldwide burden of cancer increased and is expected to worsen within the next decades. Therefore, universal combat against cancer will not succeed with treatment solely; effective prevention and early detection are urgently needed to tackle the cancer crisis. Emerging data demonstrate that long non-coding RNAs are involved in numerous biological and pathological processes like development and differentiation and in a variety of human diseases including cancer. Located at 18q21, LINC-ROR (regulator of reprogramming) is a modulator of ESCs maintenance and hypoxia-signaling pathways in hepatocellular cancer cells. The aim of this study was to examine the expression of LINC-ROR in various cell lines and representative samples of human cancers by quantitative real-time RT-PCR to provide a snapshot on how LINC-ROR expression may be deregulated in cancer. More than 30 cell lines and 112 patient specimens from various tissues were assessed for relative expression of LINC-ROR. Our results revealed that the expression of LINC-ROR was lower in all somatic cancer cell lines compared to stem cells or cells with stem cell-like capabilities, like the embryonic carcinoma cell line, NTERA-2. In tissues, expression patterns vary, but some cancerous tissues displayed increased LINC-ROR expression compared to corresponding normal tissues. Thus, we hypothesize that LINC-ROR may have a key function in a subpopulation of cells from the tumor bulk, i.e., the cancer stem cells associated with specific properties including resistance to adverse environmental conditions.

http://globocan.iarc.fr. 2014.

Consortium EP, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74. doi:10.1038/nature11247.CrossRef

Yavartanoo M, Choi JK. ENCODE: a sourcebook of epigenomes and chromatin language. Genomics Inform. 2013;11(1):2–6. doi:10.5808/GI.2013.11.1.2.CrossRefPubMedPubMedCentral

Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation. Epigenetics and human disease. ChemMedChem. 2014. doi:10.1002/cmdc.201300534.PubMed

Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–69. doi:10.1534/genetics.112.146704.CrossRefPubMedPubMedCentral

Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74. doi:10.1038/nrg3074.CrossRefPubMed

Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 2009;106(28):11667–72.CrossRefPubMedPubMedCentral

Li J, Xuan Z, Liu C. Long non-coding RNAs and complex human diseases. Int J Mol Sci. 2013;14(9):18790–808. doi:10.3390/ijms140918790.CrossRefPubMedPubMedCentral

Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147(2):358–69. doi:10.1016/j.cell.2011.09.028.CrossRefPubMedPubMedCentral

10.

Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011;147(2):344–57. doi:10.1016/j.cell.2011.09.029.CrossRefPubMedPubMedCentral

11.

Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013;25(1):69–80. doi:10.1016/j.devcel.2013.03.002.CrossRefPubMed

12.

Cheng EC, Lin H. Repressing the repressor: a lincRNA as a MicroRNA sponge in embryonic stem cell self-renewal. Dev Cell. 2013;25(1):1–2. doi:10.1016/j.devcel.2013.03.020.CrossRefPubMed

13.

Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113–7. doi:10.1038/ng.710.CrossRefPubMedPubMedCentral

14.

Zhang A, Zhou N, Huang J, Liu Q, Fukuda K, Ma D, et al. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res. 2013;23(3):340–50. doi:10.1038/cr.2012.164.CrossRefPubMed

15.

Takahashi K, Yan IK, Haga H, Patel T. Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J Cell Sci. 2014;127(Pt 7):1585–94. doi:10.1242/jcs.141069.CrossRefPubMedPubMedCentral

16.

Zhou X, Gao Q, Wang J, Zhang X, Liu K, Duan Z. Linc-RNA-RoR acts as a “sponge” against mediation of the differentiation of endometrial cancer stem cells by microRNA-145. Gynecol Oncol. 2014;133(2):333–9. doi:10.1016/j.ygyno.2014.02.033.CrossRefPubMed

17.

Nikpour P, Baygi ME, Steinhoff C, Hader C, Luca AC, Mowla SJ, et al. The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells. J Cell Mol Med. 2011;15(5):1210–24. doi:10.1111/j.1582-4934.2010.01090.x.CrossRefPubMed

18.

Baharvand H, Ashtiani SK, Taee A, Massumi M, Valojerdi MR, Yazdi PE, et al. Generation of new human embryonic stem cell lines with diploid and triploid karyotypes. Develop Growth Differ. 2006;48(2):117–28. doi:10.1111/j.1440-169X.2006.00851.x.CrossRef

19.

Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014;5:e1287. doi:10.1038/cddis.2014.249.CrossRefPubMedPubMedCentral

20.

Mitelman F, Johansson B, Mertens F, editors. Mitelman database of chromosome aberrations and gene fusions in cancer. 2015. http://cgap.nci.nih.gov/Chromosomes/Mitelman.

21.

Cai T, Nesi G, Dal Canto M, Mondaini N, Piazzini M, Bartoletti R. Prognostic role of loss of heterozygosity on chromosome 18 in patients with low-risk nonmuscle-invasive bladder cancer: results from a prospective study. J Surg Res. 2010;161(1):89–94. doi:10.1016/j.jss.2008.10.017.CrossRefPubMed

22.

Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene. 2004;23(12):2250–63. doi:10.1038/sj.onc.1207260.CrossRefPubMed

23.

Prat E, Bernues M, Caballin MR, Egozcue J, Gelabert A, Miro R. Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology. 2001;57(5):986–92.CrossRefPubMed

24.

Liu YY, Chen HY, Zhang ML, Tian D, Li S, Lee JY. Loss of fragile histidine triad and amplification of 1p36.22 and 11p15.5 in primary gastric adenocarcinomas. World J Gastroenterol WJG. 2012;18(33):4522–32. doi:10.3748/wjg.v18.i33.4522.CrossRefPubMed

25.

Hiyama T, Tanaka S, Yoshihara M, Sasao S, Kose K, Shima H, et al. Chromosomal and microsatellite instability in sporadic gastric cancer. J Gastroenterol Hepatol. 2004;19(7):756–60. doi:10.1111/j.1440-1746.2004.03369.x.CrossRefPubMed

Title: Altered expression of LINC-ROR in cancer cell lines and tissues
Authors: Majdaddin Rezaei
Modjtaba Emadi-Baygi
Michèle J. Hoffmann
Wolfgang A. Schulz
Parvaneh Nikpour
Publication date: 01-02-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3933-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules

Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemoprevention

Inhibitory effects of Arhgap6 on cervical carcinoma cells

LIM domain only 2 induces glioma invasion via cytosolic p27KIP1

PEBP4 promoted the growth and migration of cancer cells in pancreatic ductal adenocarcinoma

Fangchinoline suppresses the growth and invasion of human glioblastoma cells by inhibiting the kinase activity of Akt and Akt-mediated signaling cascades

Keynote webinar | Spotlight on antibody–drug conjugates in cancer